SCHEMBL4855348

SCHEMBL4855348

CC(N)C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 3/20 0.43
CYP2D6 P10635 2/20 0.43
CYP1A2 P05177 1/20 0.43
TAAR1 Q96RJ0 4/20 0.41
SLC6A2 P23975 2/20 0.41
MAOA P21397 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
CYP2A6 P11509 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
ADRA2A P08913 1/20 0.39
ADRA2C P18825 1/20 0.39
LMNA P02545 1/20 0.39
HIF1A Q16665 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17077295 0.82 ADRA2A (0.43) KCNN4CYP2D6CYP1A2TAAR1SLC6A2
SCHEMBL28351447 0.82 CYP1A2 (0.42) KCNN4CYP2D6CYP1A2TAAR1SLC6A2
SCHEMBL28351446 0.82 CYP1A2 (0.42) KCNN4CYP2D6CYP1A2TAAR1SLC6A2
Ammonia Solution, Strong SCHEMBL1484878 0.80 CYP1A2 (0.41) KCNN4CYP2D6CYP1A2TAAR1SLC6A2
SCHEMBL1701240 0.80 KCNN4 (0.53) KCNN4CYP2D6CYP1A2TAAR1SLC6A2
SCHEMBL5696040 0.78 KCNN4 (0.42) KCNN4CYP2D6CYP1A2TAAR1MAPK1
SCHEMBL22402881 0.78 CYP2D6 (0.46) KCNN4CYP2D6CYP1A2TAAR1HIF1A
SCHEMBL11772011 0.78 KCNN4 (0.48) KCNN4CYP2D6CYP1A2TAAR1LMNA
SCHEMBL20999978 0.77 TAAR1 (0.44) KCNN4CYP2D6CYP1A2TAAR1SLC6A2
SCHEMBL114847 0.77 KCNN4 (0.48) KCNN4CYP2D6CYP1A2TAAR1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024112201-A1 DNA GYRASE INHIBITORS UNIVERSITEIT LEIDEN (NL) 2024-05-30 WO disclosed
US-7408023-B2 Peptoids incorporating chemoselective functionalities NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-08-05 US disclosed
US-20060188916-A1 Peptoids incorporating chemoselective functionalities NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2006-08-24 US disclosed
US-7030216-B2 Peptoids incorporating chemoselective functionalities CHIRON CORPORATION (US) 2006-04-18 US disclosed
US-20020169281-A1 Peptoids incorporating chemoselective functionalities CHIRON CORPORATION 2002-11-14 US disclosed
WO-2002081637-A2 PEPTIDES INCORPORATING CHEMOSELECTIVE FUNCTIONALITIES CHIRON CORPORATION (US) 2002-10-17 WO disclosed
EP-0087709-A1 N,N',N\"-triaryl-1,2,3-triaminopropane derivatives, process for their preparation and their use as intermediates HOECHST AKTIENGESELLSCHAFT (DE) 1983-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060188916-A1 Peptoids incorporating chemoselective functionalities VIP, PCNA, DNPEP KCNN4 4438/4885CYP2D6 3499/4885CYP1A2 4586/4885
US-20020169281-A1 Peptoids incorporating chemoselective functionalities VIP, PCNA, DNPEP KCNN4 4438/4885CYP2D6 3499/4885CYP1A2 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.